Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.21 USD
Change Today +0.09 / 4.25%
Volume 39.5K
VRML On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 05/26/15 All times are local (Market data is delayed by at least 15 minutes).

vermillion inc (VRML) Snapshot

Open
$2.15
Previous Close
$2.12
Day High
$2.21
Day Low
$2.02
52 Week High
06/16/14 - $2.95
52 Week Low
12/9/14 - $1.20
Market Cap
95.3M
Average Volume 10 Days
81.1K
EPS TTM
$-0.52
Shares Outstanding
43.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VERMILLION INC (VRML)

Related News

No related news articles were found.

vermillion inc (VRML) Related Businessweek News

No Related Businessweek News Found

vermillion inc (VRML) Details

Vermillion, Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians diagnose, treat, and enhance outcomes for women. It is developing novel diagnostic tests for gynecologic disease with focus on ovarian cancer. The company’s lead product is OVA1, a blood test for pre-surgical identification of women who are at high risk of having a malignant ovarian tumor. It serves clinical reference laboratories, hospital laboratories, and physician offices in the United States. Vermillion, Inc. was founded in 1993 and is headquartered in Austin, Texas.

31 Employees
Last Reported Date: 03/31/15
Founded in 1993

vermillion inc (VRML) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: $107.3K
Principal Financial Officer, Chief Accounting...
Total Annual Compensation: $184.0K
Chief Scientific Officer, Senior Vice Preside...
Total Annual Compensation: $269.0K
Compensation as of Fiscal Year 2014.

vermillion inc (VRML) Key Developments

Vermillion, Inc. Announces Positive Top-Line Results Regarding OVA2 Development and Clinical Validation

Vermillion, Inc. announced publication of two abstracts reporting initial positive top-line results regarding the development and validation of OVA2, Vermillions second-generation OVA1 ovarian cancer triage test. The abstracts represent the first publication of data from OVA2 development, and underpin Vermillions submission of OVA2 for 510(k) clearance to the FDA. The data show significant improvement in OVA2 specificity compared to OVA1, while maintaining strong sensitivity (92% for OVA1 in a 2013 pivotal study). Vermillions goal is to launch OVA2 by the third quarter of this year, dependent on successful and timely FDA clearance. Validation of a second-generation MIA (MIA2G) for triage of adnexal masses reported on the validation of OVA2 (under a generic name, MIA2G). Across all subjects, 33% fewer benign positives were seen with OVA2 compared with OVA1. The validation study showed statistically significant improvement in specificity as a risk stratification test (OVA2 alone), with no significant reduction of sensitivity or negative predictive value (NPV). Sensitivity and NPV were not reported in the abstract, but will be shown in the poster itself as compared to OVA1. The large validation cohort also showed statistically significant improvement in positive predictive value (PPV), as well as a 12% improvement in overall test accuracy, defined as (true positives + true negatives) ÷ (N) compared to OVA1. Derivation of a second generation multivariate index assay (MIA2G) to improve specificity in pre-surgical evaluation of adnexal masses for risk of ovarian cancer. As a result of the development work, OVA2 will measure a woman’s risk of cancer using a 0 to 10 scale, as with the OVA1 test. OVA2, however, has a single cutoff; less than 5.0 for low risk and greater than or equal to 5.0 for high risk. This design greatly simplifies testing procedures and interpretation.

Vermillion, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Vermillion, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenue of $951,000 against $305,000 a year ago. Loss from operations was $4,262,000 against $3,995,000 a year ago. Net loss was $4,137,000 against $3,987,000 a year ago. Basic and diluted net loss per share was $0.10 against $0.11 a year ago. The company has no remaining debt as of March 31, 2015. The company utilized $4.5 million in cash in operations in the first quarter as well as the $1.1 million for the repayment of short-term debt.

Vermillion, Inc. to Report Q1, 2015 Results on May 11, 2015

Vermillion, Inc. announced that they will report Q1, 2015 results at 4:30 PM, US Eastern Standard Time on May 11, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRML:US $2.21 USD +0.09

VRML Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arrayit Corp $0.0038 USD +0.0003
Imperial Innovations Group PLC 475.00 GBp +5.00
Jeol Ltd ¥592.00 JPY +4.00
MDxHealth €4.95 EUR -0.101
Miraculins Inc C$0.10 CAD 0.00
View Industry Companies
 

Industry Analysis

VRML

Industry Average

Valuation VRML Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 28.9x
Price/Book 6.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 23.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERMILLION INC, please visit www.vermillion.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.